{"title":"Massage Therapists (Sex Workers) and Mpox in the Philippines.","authors":"Dalmacito A Cordero","doi":"10.1093/infdis/jiae517","DOIUrl":"https://doi.org/10.1093/infdis/jiae517","url":null,"abstract":"","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Broadening the Global Mpox Response: A Critical Reflection on Vulnerable Populations.","authors":"Yusuff Adebayo Adebisi","doi":"10.1093/infdis/jiae518","DOIUrl":"https://doi.org/10.1093/infdis/jiae518","url":null,"abstract":"","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Vaccines for Global Health: Progress and Challenges.","authors":"Jane M Knisely,Emily Erbelding","doi":"10.1093/infdis/jiae511","DOIUrl":"https://doi.org/10.1093/infdis/jiae511","url":null,"abstract":"","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christopher N Selverian,Stephanie R Monticelli,Yakin M Jaleta,Gorka Lasso,Megan E DeMouth,Annalisa Meola,Jacob Berrigan,Thomas G Batchelor,Leandro Battini,Pablo Guardado-Calvo,Andrew S Herbert,Kartik Chandran,Eric Meyerowitz,Emily Happy Miller
Monkeypox virus (MPXV) has recently caused a global disease outbreak in humans. Differences in the neutralizing antibody response to vaccination vs. MPXV infection remain poorly understood. Here, we examined the neutralization of MPXV and VACV by sera from a cohort of convalescent and vaccinated individuals at 1- and 8-months post-exposure. Convalescent individuals displayed higher neutralizing antibody titers against MPXV than vaccinated and MPXV-naïve persons at one-month post-exposure. Neutralizing antibody titers had waned significantly in both groups at 8 months. This study suggests additional vaccine strategies are needed to elicit a durable humoral response and prevent breakthrough infections.
{"title":"MPXV Infection Stimulates a More Robust and Durable Neutralizing Antibody Response Compared to MVA-BN Vaccination.","authors":"Christopher N Selverian,Stephanie R Monticelli,Yakin M Jaleta,Gorka Lasso,Megan E DeMouth,Annalisa Meola,Jacob Berrigan,Thomas G Batchelor,Leandro Battini,Pablo Guardado-Calvo,Andrew S Herbert,Kartik Chandran,Eric Meyerowitz,Emily Happy Miller","doi":"10.1093/infdis/jiae515","DOIUrl":"https://doi.org/10.1093/infdis/jiae515","url":null,"abstract":"Monkeypox virus (MPXV) has recently caused a global disease outbreak in humans. Differences in the neutralizing antibody response to vaccination vs. MPXV infection remain poorly understood. Here, we examined the neutralization of MPXV and VACV by sera from a cohort of convalescent and vaccinated individuals at 1- and 8-months post-exposure. Convalescent individuals displayed higher neutralizing antibody titers against MPXV than vaccinated and MPXV-naïve persons at one-month post-exposure. Neutralizing antibody titers had waned significantly in both groups at 8 months. This study suggests additional vaccine strategies are needed to elicit a durable humoral response and prevent breakthrough infections.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Esther Truscello,Shouao Wang,Jim Young,Giada Sebastiani,Sharon L Walmsley,Mark Hull,Curtis Cooper,Marina B Klein
BACKGROUNDBoth HIV and hepatitis C virus (HCV) infection increase the risk of hepatic steatosis (HS), which in turn contributes to the severity and progression of liver disease. Direct acting antivirals (DAAs) can cure HCV but whether they reduce HS is unclear.METHODSHS was assessed using the controlled attenuation parameter (CAP) and the hepatic steatosis index (HSI) in participants coinfected with HIV-HCV from the Canadian Coinfection Cohort. Changes in HS, before, during and after successful DAA treatment, were estimated using generalized additive mixed models, adjusted for covariates measured prior to treatment (age, sex, duration of HCV infection, body mass index, diabetes, prior exposure to dideoxynucleosides and hazardous drinking).RESULTS431 participants with at least one measure of CAP or HSI before treatment were included. CAP steadily increased over time: adjusted annual slope 3.3 dB/m (95% credible interval (CrI) 1.6, 4.9) before, and 3.9 dB/m (95% CrI: 1.9, 5.9) after DAA treatment, irrespective of pre-treatment CAP. In contrast, HSI changed little over time: annual slope 0.2 (95% CrI: -0.1, 0.5) before and 0.2 (95% CrI -0.1, 0.5) after, but demonstrated a marked reduction during treatment -4.5 (95% CrI -5.9, -3.1).CONCLUSIONSWhen assessed by CAP, HS was unaffected by DAA treatment and steadily increased over time. In contrast, HSI did not appear to reflect changes in HS, with the decrease during treatment likely related to resolution of hepatic inflammation. Ongoing HS may pose a risk for liver disease in coinfected people cured of HCV.
{"title":"Changes in hepatic steatosis before and after direct acting antiviral treatment in people living with HIV and Hepatitis C coinfection.","authors":"Esther Truscello,Shouao Wang,Jim Young,Giada Sebastiani,Sharon L Walmsley,Mark Hull,Curtis Cooper,Marina B Klein","doi":"10.1093/infdis/jiae487","DOIUrl":"https://doi.org/10.1093/infdis/jiae487","url":null,"abstract":"BACKGROUNDBoth HIV and hepatitis C virus (HCV) infection increase the risk of hepatic steatosis (HS), which in turn contributes to the severity and progression of liver disease. Direct acting antivirals (DAAs) can cure HCV but whether they reduce HS is unclear.METHODSHS was assessed using the controlled attenuation parameter (CAP) and the hepatic steatosis index (HSI) in participants coinfected with HIV-HCV from the Canadian Coinfection Cohort. Changes in HS, before, during and after successful DAA treatment, were estimated using generalized additive mixed models, adjusted for covariates measured prior to treatment (age, sex, duration of HCV infection, body mass index, diabetes, prior exposure to dideoxynucleosides and hazardous drinking).RESULTS431 participants with at least one measure of CAP or HSI before treatment were included. CAP steadily increased over time: adjusted annual slope 3.3 dB/m (95% credible interval (CrI) 1.6, 4.9) before, and 3.9 dB/m (95% CrI: 1.9, 5.9) after DAA treatment, irrespective of pre-treatment CAP. In contrast, HSI changed little over time: annual slope 0.2 (95% CrI: -0.1, 0.5) before and 0.2 (95% CrI -0.1, 0.5) after, but demonstrated a marked reduction during treatment -4.5 (95% CrI -5.9, -3.1).CONCLUSIONSWhen assessed by CAP, HS was unaffected by DAA treatment and steadily increased over time. In contrast, HSI did not appear to reflect changes in HS, with the decrease during treatment likely related to resolution of hepatic inflammation. Ongoing HS may pose a risk for liver disease in coinfected people cured of HCV.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142448002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The development of SARS-CoV-2 next-generation vaccines with the potential for increased effectiveness, durability, breadth, and ability to decrease transmission are of public health importance. We highlight alternative routes of administration of next-generation SARS-CoV-2 vaccines such as mucosal and intradermal administration.
{"title":"Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration.","authors":"Tara M Babu,Lisa A Jackson,Hana M El Sahly","doi":"10.1093/infdis/jiae504","DOIUrl":"https://doi.org/10.1093/infdis/jiae504","url":null,"abstract":"The development of SARS-CoV-2 next-generation vaccines with the potential for increased effectiveness, durability, breadth, and ability to decrease transmission are of public health importance. We highlight alternative routes of administration of next-generation SARS-CoV-2 vaccines such as mucosal and intradermal administration.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Saranathan Rajagopalan,Amy K Rourke,Emmanuel Asare,Donna J Kohlerschmidt,Lahari Das,Senamile L Ngema,Claire V Mulholland,Catherine Vilchèze,Vaishnavi Mahalingam,Sashen Moodley,Barry Truebody,Jared Mackenzie,Adrie J C Steyn,Rubeshan Perumal,Michael Berney,Michelle H Larsen,Max R O'Donnell,Vincent E Escuyer,William R Jacobs
BACKGROUNDDrug-resistant tuberculosis is a growing public health threat, and early characterization of the resistance phenotype is essential for guiding treatment and mitigating the high mortality associated with the disease. However, the slow growth rate of Mycobacterium tuberculosis, the causative agent of tuberculosis, necessitates several weeks for conventional culture-dependent drug susceptibility testing (DST). In addition, there are no widely available molecular diagnostic assays for evaluating resistance to newer tuberculosis drugs or drugs with complex resistance mechanisms.METHODSWe have developed a luciferase-based reporter mycobacteriophage assay that can determine drug resistance within 48 hours. We engineered the TM4 mycobacteriophage to express green enhanced nanoluciferase (GeNL) cassette and optimized DST for bedaquiline, pretomanid, linezolid, clofazimine, and rifampicin using clinical M. tuberculosis isolates.RESULTSTo assess the feasibility of this assay, we conducted a proof-of-principle study using 53 clinical M. tuberculosis isolates. TM4::GeNL phage DST effectively distinguished between sensitive and resistant isolates for bedaquiline and rifampicin at a concentration of 0.125 μg/mL. Optimal differentiation between sensitive and resistant isolates for pretomanid, clofazimine, and linezolid was achieved at concentrations of 0.5 μg/mL, 0.25 μg/mL, and 1 μg/mL, respectively. Additionally, TM4::GeNL DST identified low-level rifampicin resistance in clinical isolates even though they were classified as sensitive by Mycobacteria Growth Indicator Tube DST.CONCLUSIONSTM4::GeNL reporter phage DST offers a rapid method to identify M. tuberculosis drug resistance, including resistance to newer tuberculosis drugs.
{"title":"Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates.","authors":"Saranathan Rajagopalan,Amy K Rourke,Emmanuel Asare,Donna J Kohlerschmidt,Lahari Das,Senamile L Ngema,Claire V Mulholland,Catherine Vilchèze,Vaishnavi Mahalingam,Sashen Moodley,Barry Truebody,Jared Mackenzie,Adrie J C Steyn,Rubeshan Perumal,Michael Berney,Michelle H Larsen,Max R O'Donnell,Vincent E Escuyer,William R Jacobs","doi":"10.1093/infdis/jiae438","DOIUrl":"https://doi.org/10.1093/infdis/jiae438","url":null,"abstract":"BACKGROUNDDrug-resistant tuberculosis is a growing public health threat, and early characterization of the resistance phenotype is essential for guiding treatment and mitigating the high mortality associated with the disease. However, the slow growth rate of Mycobacterium tuberculosis, the causative agent of tuberculosis, necessitates several weeks for conventional culture-dependent drug susceptibility testing (DST). In addition, there are no widely available molecular diagnostic assays for evaluating resistance to newer tuberculosis drugs or drugs with complex resistance mechanisms.METHODSWe have developed a luciferase-based reporter mycobacteriophage assay that can determine drug resistance within 48 hours. We engineered the TM4 mycobacteriophage to express green enhanced nanoluciferase (GeNL) cassette and optimized DST for bedaquiline, pretomanid, linezolid, clofazimine, and rifampicin using clinical M. tuberculosis isolates.RESULTSTo assess the feasibility of this assay, we conducted a proof-of-principle study using 53 clinical M. tuberculosis isolates. TM4::GeNL phage DST effectively distinguished between sensitive and resistant isolates for bedaquiline and rifampicin at a concentration of 0.125 μg/mL. Optimal differentiation between sensitive and resistant isolates for pretomanid, clofazimine, and linezolid was achieved at concentrations of 0.5 μg/mL, 0.25 μg/mL, and 1 μg/mL, respectively. Additionally, TM4::GeNL DST identified low-level rifampicin resistance in clinical isolates even though they were classified as sensitive by Mycobacteria Growth Indicator Tube DST.CONCLUSIONSTM4::GeNL reporter phage DST offers a rapid method to identify M. tuberculosis drug resistance, including resistance to newer tuberculosis drugs.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"209 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUNDHIV/AIDS among the elderly presents a new public health challenge in China. We aimed to explore historical trends (2004-2018) and project the future (2019-2030) burden of HIV/AIDS incidence and mortality among the elderly in China.METHODSWe utilized data from the Data Center of China Public Health Science database on HIV/AIDS incidence and mortality, employing the Bayesian age-period-cohort model to reveal the age-period-cohort effect in the HIV/AIDS burden, and projecting the incidence and mortality rates up to 2030.RESULTSFrom 2004 to 2018, HIV/AIDS incidence rates increased from 0.56/105 to 20.78/105 for men and 0.28/105 to 7.84/105 for women. The mortality rates also elevated in both genders. We observed the highest age effect in incidence among the men aged 70-74 and women aged 55-59, with the effect estimates being 0.02 (95% CI: -0.10 to 0.13) and 0.46 (95% CI: 0.35 to 0.57). Similar gender disparities were observed for the mortality, with the highest age effect observed in men aged 75-79 and women aged 50-54. However, no significant disparities were found between men and women in the period and cohort effects. By 2030, the incidence rates were projected to be 96.25/105 in men and 44.90/105 in women, while the mortality rates were projected to be 48.27/105 and 13.67/105.CONCLUSIONHIV/AIDS incidence and mortality rates rose notably among the elderly in China and are expected to keep increasing in the coming decades. Rates were consistently higher in men than in women. Tailored interventions for older men are crucial.
{"title":"Trends, Age-Period-Cohort Effects, and Projections in the Incidence and Mortality of HIV/AIDS among the Elderly in China.","authors":"Jinwei Chen,Yikun Chang,Yueqian Wu,Hui Tang,Gonghua Wu,Jie Sun,Pengyu Wang,Yuantao Hao,Wangjian Zhang,Zhicheng Du","doi":"10.1093/infdis/jiae485","DOIUrl":"https://doi.org/10.1093/infdis/jiae485","url":null,"abstract":"BACKGROUNDHIV/AIDS among the elderly presents a new public health challenge in China. We aimed to explore historical trends (2004-2018) and project the future (2019-2030) burden of HIV/AIDS incidence and mortality among the elderly in China.METHODSWe utilized data from the Data Center of China Public Health Science database on HIV/AIDS incidence and mortality, employing the Bayesian age-period-cohort model to reveal the age-period-cohort effect in the HIV/AIDS burden, and projecting the incidence and mortality rates up to 2030.RESULTSFrom 2004 to 2018, HIV/AIDS incidence rates increased from 0.56/105 to 20.78/105 for men and 0.28/105 to 7.84/105 for women. The mortality rates also elevated in both genders. We observed the highest age effect in incidence among the men aged 70-74 and women aged 55-59, with the effect estimates being 0.02 (95% CI: -0.10 to 0.13) and 0.46 (95% CI: 0.35 to 0.57). Similar gender disparities were observed for the mortality, with the highest age effect observed in men aged 75-79 and women aged 50-54. However, no significant disparities were found between men and women in the period and cohort effects. By 2030, the incidence rates were projected to be 96.25/105 in men and 44.90/105 in women, while the mortality rates were projected to be 48.27/105 and 13.67/105.CONCLUSIONHIV/AIDS incidence and mortality rates rose notably among the elderly in China and are expected to keep increasing in the coming decades. Rates were consistently higher in men than in women. Tailored interventions for older men are crucial.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Combination seasonal vaccines for influenza, RSV, SARS-CoV-2, and other pathogens.","authors":"David Dobrzynski,Angela R Branche,Ann R Falsey","doi":"10.1093/infdis/jiae507","DOIUrl":"https://doi.org/10.1093/infdis/jiae507","url":null,"abstract":"","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David N Hager,Yuwei Zhu,Ine Sohn,William B Stubblefield,Michael B Streiff,Manjusha Gaglani,Jay S Steingrub,Abhijit Duggal,Jamie R Felzer,Mary O'Rourke,Ithan D Peltan,Amira Mohamed,Robin Stiller,Jennifer G Wilson,Nida Qadir,Adit A Ginde,Anne E Zepeski,Christopher Mallow,Adam S Lauring,Nicholas J Johnson,Kevin W Gibbs,Jennie H Kwon,Wesley H Self,
BACKGROUNDCOVID-19 is a strong risk factor for venous thromboembolism (VTE). Few studies have evaluated the effectiveness of COVID-19 vaccination in preventing hospitalization for COVID-19 with VTE.METHODSAdults hospitalized at 21 sites between March 2021 and October 2022 with symptoms of acute respiratory illness were assessed for COVID-19, completion of the original monovalent mRNA COVID-19 vaccination series, and VTE. Prevalence of VTE was compared between unvaccinated and vaccinated patients with COVID-19. Vaccine effectiveness in preventing COVID-19 hospitalization with VTE was calculated using a test negative design. Vaccine effectiveness was also stratified by predominant circulating SARS-CoV-2 variant.RESULTSAmong 18,811 patients (median age 63 [IQR:50-73], 49% women, 59% non-Hispanic White, 20% non-Hispanic Black, 14% Hispanic, and median of 2 comorbid conditions [IQR:1-3]), 9,792 were admitted with COVID-19 (44% vaccinated) and 9,019 were test-negative controls (73% vaccinated). Among patients with COVID-19, 601 were diagnosed with VTE by hospital day 28, of whom 170 were vaccinated. VTE was more common among unvaccinated than vaccinated COVID-19 patients (7.8% versus 4.0%; p=0.001). Vaccine effectiveness against COVID-19 hospitalization with VTE was 84% (95% CI: 80-87%) overall. Vaccine effectiveness stratified by predominant circulating variant was 88% (73-95%) for alpha, 93% (90-95%) for delta, and 68% (58-76%) for omicron variants.CONCLUSIONS AND RELEVANCEVaccination with the original monovalent mRNA series was associated with a decrease in COVID-19 hospitalization with VTE, though data detailing prior history of VTE and use of anticoagulation were not available. These findings will inform risk-benefit considerations for those considering vaccination.
{"title":"Effectiveness of the original monovalent mRNA COVID-19 vaccination series against hospitalization for COVID-19-associated venous thromboembolism.","authors":"David N Hager,Yuwei Zhu,Ine Sohn,William B Stubblefield,Michael B Streiff,Manjusha Gaglani,Jay S Steingrub,Abhijit Duggal,Jamie R Felzer,Mary O'Rourke,Ithan D Peltan,Amira Mohamed,Robin Stiller,Jennifer G Wilson,Nida Qadir,Adit A Ginde,Anne E Zepeski,Christopher Mallow,Adam S Lauring,Nicholas J Johnson,Kevin W Gibbs,Jennie H Kwon,Wesley H Self,","doi":"10.1093/infdis/jiae502","DOIUrl":"https://doi.org/10.1093/infdis/jiae502","url":null,"abstract":"BACKGROUNDCOVID-19 is a strong risk factor for venous thromboembolism (VTE). Few studies have evaluated the effectiveness of COVID-19 vaccination in preventing hospitalization for COVID-19 with VTE.METHODSAdults hospitalized at 21 sites between March 2021 and October 2022 with symptoms of acute respiratory illness were assessed for COVID-19, completion of the original monovalent mRNA COVID-19 vaccination series, and VTE. Prevalence of VTE was compared between unvaccinated and vaccinated patients with COVID-19. Vaccine effectiveness in preventing COVID-19 hospitalization with VTE was calculated using a test negative design. Vaccine effectiveness was also stratified by predominant circulating SARS-CoV-2 variant.RESULTSAmong 18,811 patients (median age 63 [IQR:50-73], 49% women, 59% non-Hispanic White, 20% non-Hispanic Black, 14% Hispanic, and median of 2 comorbid conditions [IQR:1-3]), 9,792 were admitted with COVID-19 (44% vaccinated) and 9,019 were test-negative controls (73% vaccinated). Among patients with COVID-19, 601 were diagnosed with VTE by hospital day 28, of whom 170 were vaccinated. VTE was more common among unvaccinated than vaccinated COVID-19 patients (7.8% versus 4.0%; p=0.001). Vaccine effectiveness against COVID-19 hospitalization with VTE was 84% (95% CI: 80-87%) overall. Vaccine effectiveness stratified by predominant circulating variant was 88% (73-95%) for alpha, 93% (90-95%) for delta, and 68% (58-76%) for omicron variants.CONCLUSIONS AND RELEVANCEVaccination with the original monovalent mRNA series was associated with a decrease in COVID-19 hospitalization with VTE, though data detailing prior history of VTE and use of anticoagulation were not available. These findings will inform risk-benefit considerations for those considering vaccination.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：